Navigation Links
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Date:5/13/2008

Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients

Treated with TAXUS

BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Long-term data presented for the first time today from the SPIRIT III trial, Abbott's U.S. pivotal trial studying the XIENCE(TM) V Everolimus Eluting Coronary Stent System, demonstrated that XIENCE V continues to deliver clinically superior benefits for patients compared to the TAXUS(R) paclitaxel-eluting coronary stent system. In this trial of more than 1,000 patients, XIENCE V demonstrated a 45 percent reduction in the risk of major adverse cardiac events (MACE) and a 32 percent reduction in the risk of target vessel failure (cardiac events related to the treated vessel) at two years as compared to TAXUS. The SPIRIT III two-year results were presented by Gregg W. Stone, M.D., principal investigator of the SPIRIT III trial, during the late-breaking clinical trials session at EuroPCR 2008.

"Not only did XIENCE V clearly differentiate itself from the TAXUS stent in the first year after treatment, it has now demonstrated even more positive effects at two years in the SPIRIT III trial," said Dr. Stone, Columbia University Medical Center and chairman, Cardiovascular Research Foundation, New York. "As measured by clinically significant reductions in target vessel failure and MACE, XIENCE V demonstrated an even greater improvement in patient outcomes compared to TAXUS at two years than at one year, driven by numerically lower rates of heart attacks and lower observed rates of re-intervention of the target lesion. We also saw encouraging trends for lower observed rates of late and very late stent thrombosis in XIENCE V-treated patients, especially in those who discontinued dual antiplatelet therapy."

The SPIRIT III trial of 1,002 patients, which is the basis for the pre- market application of XIENCE V to
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
2. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
5. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
6. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
7. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
8. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
9. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Reportlinker.com announces that a new ... Germany Aesthetic Lasers and Energy Devices ... http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Germany Aesthetic Lasers and ... GlobalData,s new report, "Germany Aesthetic Lasers and ... market data on the Germany Aesthetic Lasers and ...
(Date:8/28/2014)... N.J. , Aug. 28, 2014 /PRNewswire-iReach/ -- ... medical device space, is excited to announce they ... the VIEW Plating System and REDUCE Fracture Plating ... anatomic plates used to support multiple indications within ... packaged Lapidus, First Metatarsophalangeal (MTP), Calcaneal-Cuboid (CC), Talonavicular ...
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite ... graduates, has published a case study highlighting ... Excellence Course . In September and October 2014, Academy ... to Albuquerque , Indianapolis , Salt ... Photo - http://photos.prnewswire.com/prnh/20140828/140814 Leadership ...
Breaking Medicine Technology:Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9EDGE Orthopaedics Receives Second FDA Clearance 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
(Date:8/28/2014)... American adults who are beginning to ... will now have a simpler way to connect with ... this year, some of the best life insurance rates ... , The promoted plans that included price data revealed ... popular policies. The term, guaranteed and modified plans that ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 ... bellwether trial of a transvaginal mesh lawsuit ( ... Inc., Bernstein Liebhard LLP reports. Court documents pending ... West Virginia indicate that the case was filed ... undergo two revision surgeries, allegedly due to vaginal ...
(Date:8/28/2014)... Vernon, Ind. (PRWEB) August 28, 2014 ... of Valero Energy Corporation (NYSE: VLO), and the Ports ... state and local officials today at a Port Appreciation ... purchased Mount Vernon ethanol plant. , “The opening of ... Vernon is another economic development win for the ...
(Date:8/28/2014)... take wing? Did they fall from trees and learn to ... along the ground and pump their "arms" to get aloft? ... past, but a new University of California, Berkeley, study provides ... ability to maneuver in midair, a talent that could have ... a perch. , The study looked at how baby birds, ...
(Date:8/28/2014)... of Medicine published research results on Aug. 21 ... safely reduce the viral load and clinical illness of ... (RSV). , Le Bonheur Children,s Hospital and ... Disease Specialist John DeVincenzo, MD, is lead author of ... common cause of lower respiratory tract infections in young ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:DeVincenzo study breakthrough in RSV research 2
... will save lives this holiday season, NEW ... Friday" and the holiday season, New York Blood ... the children and,families whose lives are stricken by ... survival. Among these diseases are: Leukemia,and other forms ...
... efforts through second Innovation Event, INDIANAPOLIS, ... WLP ), the,nation,s largest health insurance company ... will begin accepting applications for its second ... innovation,partnership efforts by providing an accelerated process ...
... lead to vaccine that works , , THURSDAY, Nov. 13 (HealthDay ... has failed, but researchers report that they,ve still gained insight ... "It,s raised a whole new set of questions that are ... to a successful vaccine," said Dr. Susan P. Buchbinder, lead ...
... ... hospitals, ... announced HealthBIT, a healthcare business intelligence platform for,hospitals. HealthBIT(TM) provides ... and comparing their,data to provide actionable opportunities that result in ...
... shows economic,stress takes toll on the emotional and ... conducted by the American Psychological Association, shows,at least ... economy as their top,stressors. More than half, reported ... anger. Forty-six percent indicated they,were worried about providing ...
... options dwindle or are exhausted, terminally ill-patients often ... therapies. However, a team of researchers from Wake ... Medical Center and Unity Health System, report that ... governing end-of-life care may be leaving many medical ...
Cached Medicine News:Health News:A Thanksgiving Message From New York Blood Center 2Health News:A Thanksgiving Message From New York Blood Center 3Health News:WellPoint Announces Second Annual Innovation Event 2Health News:WellPoint Announces Second Annual Innovation Event 3Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform 2Health News:Economic Stress Takes Toll on Health 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 3
For the quantitative in vitro determination of CK-MB in serum and plasma...
The ALT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alanine aminotransferase activity in serum or plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... S-1™ Biodegradable Anteroir Cervical System, in conjunction ... with a collar), is intended for use ... fusion procedures as a means to maintain ... or autografts., This device is not intended ...
Medicine Products: